All You Need to Know About Vivos Therapeutics (VVOS) Rating Upgrade to Buy
Portfolio Pulse from
Vivos Therapeutics (VVOS) has been upgraded to a Zacks Rank #2 (Buy), indicating increased optimism about its earnings prospects, which could lead to a rise in its stock price.
December 18, 2024 | 6:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Vivos Therapeutics has received a Zacks Rank #2 (Buy) upgrade, suggesting positive sentiment towards its earnings potential and likely boosting its stock price.
The upgrade to a Zacks Rank #2 (Buy) reflects increased optimism about Vivos Therapeutics' earnings prospects. Such upgrades typically lead to positive investor sentiment and can result in a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100